Starpharma Holdings Ltd (ASX:SPL) is advancing its move into targeted radiopharmaceuticals, with its lead cancer program approaching a first-in-human clinical trial following alignment with the US Food and Drug Administration. At the close of 12 August 2026, Starpharma shares were trading at A$0.70, down 5.44% on the day.

What is driving the story?

The central focus is Starpharma's move into targeted radiotherapy.

Its lead asset, DEP HER2-Lu, uses the company's dendrimer technology to deliver the radioisotope lutetium-177 to HER2-positive cancers, including gastric tumours.

A significant milestone came in April 2026 when Starpharma reached alignment with the FDA following a Type C meeting. The discussions supported the company's proposed clinical strategy and study design for the DEP HER2-Lu Phase 1 trial.

The company has completed site selection and is targeting a first-in-human Phase 1 trial in Europe during the second half of calendar 2026.

Latest ASX announcements

The FDA Type C meeting alignment announced on 29 April 2026 represented an important regulatory milestone for the DEP HER2-Lu program.

Starpharma also confirmed that GMP manufacture of the drug product had been completed, supporting preparations for clinical development.

On the commercial side, Starpharma has an option agreement with Radiopharm Theranostics that includes a $0.5 million upfront payment and potential milestones of up to $91 million, together with royalties.

The company's FY26 updates also highlighted customer receipts of $12.3 million, an increase of 149%, supported by a one-off payment from Genentech and growth in Viraleze online sales.

These developments illustrate Starpharma's strategy of generating commercial value from its technology platform while advancing its own radiopharmaceutical pipeline.

Financial position

Starpharma reported approximately $11.0 million in cash at the end of June 2026.

Quarterly cash burn was approximately $3.2 million, meaning continued clinical development will require careful management of available funds.

FY26 customer receipts of $12.3 million included a significant one-off Genentech payment, meaning recurring receipts are lower than the headline figure suggests.

Potential payments under the Radiopharm agreement are also conditional on the achievement of specified milestones.

The company's future funding requirements will therefore depend on the pace of clinical development, commercial receipts, partnerships and other sources of capital.

Bull case

The positive case for Starpharma is centred on its entry into targeted radiotherapy and the regulatory progress achieved for DEP HER2-Lu.

FDA alignment on the proposed Phase 1 clinical strategy represents an important development as the company moves its lead program towards human testing.

The dendrimer platform also has potential applications beyond HER2. Starpharma has identified additional targets, including PSMA and EGFR, providing opportunities to expand its radiopharmaceutical pipeline.

Commercial agreements with pharmaceutical partners provide another potential source of value for the technology.

If DEP HER2-Lu produces encouraging safety and efficacy results in clinical testing, the company's radiopharmaceutical strategy could gain further validation.

Bear case

The principal risk is that DEP HER2-Lu has not yet generated human clinical data.

First-in-human clinical development can produce unexpected safety, efficacy or operational outcomes, and delays can materially affect the development timeline.

Funding is another consideration. With approximately $11 million in cash at the end of June and ongoing cash expenditure, Starpharma may require additional funding as its clinical programs progress.

Potential milestone payments are conditional rather than guaranteed, while reported customer receipts have benefited from one-off payments.

Competition in targeted radiopharmaceuticals is also significant, with companies developing therapies against several of the same cancer targets.

What could move the shares next?

The key upcoming milestone is the commencement of the DEP HER2-Lu Phase 1 trial, which Starpharma is targeting for the second half of calendar 2026.

Confirmation that the trial has begun dosing patients would mark an important transition from preclinical development to clinical testing.

Subsequent safety and efficacy data will become increasingly important as the program progresses.

The market will also be watching Starpharma's cash position, development expenditure, potential licensing agreements and progress with additional dendrimer-based programs.

Bottom line

Starpharma Holdings Ltd (ASX:SPL) is entering an important phase of its development as it moves its radiopharmaceutical strategy towards clinical testing.

The company has achieved FDA alignment for its DEP HER2-Lu Phase 1 program, completed GMP Manufacturing and established commercial arrangements around its technology platform.

However, the lead program remains pre-clinical from a human-testing perspective, while the company's available cash and ongoing expenditure make funding an important consideration.

At the close of 12 August 2026, Starpharma shares traded at A$0.70, down 5.44% on the day.

The commencement of the DEP HER2-Lu Phase 1 trial and subsequent clinical data are likely to be the most important developments in determining whether the company's radiopharmaceutical strategy can deliver further validation.